Seer, Inc. (SEER) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Seer, Inc. is a life sciences company focused on capturing deep molecular insights from the proteome using its proprietary Proteograph Product Suite. This report covers the quarterly period ended September 30, 2024. The company is classified as a smaller reporting company and a non-accelerated filer. As of November 4, 2024, the company had 54,921,591 shares of Class A common stock and 4,044,969 shares of Class B common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $4.0 million | $4.2 million | $10.2 million | $12.2 million |
| Gross Profit | $1.9 million | $2.2 million | $5.0 million | $6.5 million |
| Net Loss | $(21.3) million | $(21.1) million | $(64.9) million | $(68.5) million |
| Operating Cash Flow | N/A | N/A | $(34.7) million | $(48.9) million |
| Cash & Investments | $247.6 million | N/A | N/A | N/A |
| Accumulated Deficit | $(370.6) million | N/A | N/A | N/A |
Note: Cash and investments include $37.6 million in cash equivalents and $274.9 million in short-term and long-term investments as of September 30, 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3% in Q3 2024 compared to Q3 2023, primarily due to the cessation of grant revenue recognition. Year-to-date revenue decreased 17%.
- Related Party Revenue Drop: Revenue from the related party PrognomiQ, Inc. dropped significantly, representing 14% of total revenue in Q3 2024 compared to 34% in Q3 2023.
- Expense Reduction: Operating expenses decreased 6% in Q3 2024 and 7% YTD 2024 compared to prior year periods, driven by lower headcount and reduced stock-based compensation.
- Share Repurchases: The company repurchased 3.7 million shares of Class A common stock in Q3 2024 for approximately $6.6 million. Approximately $14.7 million remains available under the $25.0 million repurchase program.
- Investment Activity: The company purchased $10.0 million of PrognomiQ's Series D Preferred Stock in August 2024.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash, cash equivalents, and investments ($247.6 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring significant operating losses.
- Commercialization: The company is in the early stages of commercializing the Proteograph Product Suite. Success depends on broad scientific and market acceptance, which remains uncertain.
- Subsequent Event: On October 4, 2024, the Board approved an option repricing for certain stock options with exercise prices greater than $2.00, resetting the price to $2.00 per share.
- Risk Factors: Key risks include the company's history of net losses, dependence on a limited number of customers (including PrognomiQ), reliance on a single contract manufacturer (Hamilton Company) for instruments, and potential regulatory changes regarding research-use-only (RUO) products.
Investor Verification Checklist
- Related Party Dependence: Verify the sustainability of revenue from PrognomiQ, Inc., which accounted for 20% of YTD 2024 revenue but has shown a declining trend.
- Share Repurchase Impact: Assess the impact of the $10.4 million spent on share repurchases YTD 2024 on the company's cash runway given the continued operating losses.
- Grant Revenue Cessation: Confirm the reasons for the complete absence of grant revenue in 2024 compared to $1.2 million in 2023 and the implications for future funding.
- Option Repricing: Review the terms of the October 2024 option repricing and its potential impact on future stock-based compensation expenses and dilution.
- Manufacturing Concentration: Evaluate the risk associated with relying on a single third-party manufacturer (Hamilton Company) for the SP100 automation instrument.